31 results about "Giant cell" patented technology

Described herein are methods of treating cancers and other tumors related to the decreased proliferation, the depletion, or the repolarization of tumor-associated macrophages (TAMs) and treatment of associated disorders, including tenosynovial giant cell tumor (TGCT) and diffuse-type tenosynovial giant cell tumor (DTGCT).

Described herein are methods of treating cancers and other tumors related to the decreased proliferation, the depletion, or the repolarization of tumor-associated macrophages (TAMs) and treatment of associated disorders, including tenosynovial giant cell tumor (TGCT) and diffuse-type tenosynovial giant cell tumor (DTGCT).

Provided is a promoter having high activity in an activated T-cell. The promoter comprises, from 5′-end to 3′-end, a CMV enhancer, an IFNγ promoter, and a long terminal repeat sequence from human T-cell leukemia virus that are connected in sequence. The promoter exhibits greater activity in an activated immune cell than the existing promoters and is low in activity or inactive in other non-immune cells.

Oligomer nucleotides, compositions, methods, kits, and uses are provided for detecting or quantifying a Human Cytomegalovirus virus 1 (CMV (human herpesvirus 5, HHV5) nucleic acid, e.g., using nucleic acid amplification and hybridization assays. Multiphase amplification of a CMV target sequence is also described. The oligomer nucleotides, compositions, methods, kits, and uses can be used to amplify and / or detect the UL56 gene of CMV.

The invention features lentiviral transfer vectors that include heterologous nucleic acids to be introduced into a cell. The lentiviral transfer vector may be characterized by the following features: (a) including a cytomegalovirus (CMV) promoter; (b) including a polynucleotide encoding a partial gag protein that includes a mutated INS1 inhibitory sequence that reduces restriction of nuclear export of RNA; (c) not including a polynucleotide encoding the INS2, INS3, and INS4 inhibitory sequences of gag; (d) not including an SV40 origin of replication and / or an f1 origin of replication; (e) including a cPPT sequence that contains splice site; (f) including an EF1alpha promoter with intact splice donor and acceptor sites; and (g) including hepatitis B PRE with mutation in start codon of X protein ORF.

The present invention relates to a treatment regime, including an antibody or antigen-binding fragment which is capable of binding specifically to colony stimulating factor-1 receptor (CSF-1R) for use in the treatment of tenosynovial giant cell tumour (TGCT) in a subject, as well as associated uses and methods.

Nucleic acid molecules comprising truncated forms of the human cytomegalovirus (CMV) promoter are operably linked to a transgene of interest, including those encoding eNOS protein are taught. Vectors comprising these nucleic acid molecules and host cells transformed by these vectors and methods of producing cellular compositions are used for the treatment of a variety of pulmonary and cardiac diseases. There is provided a truncated human cytomegalovirus (CMV) enhancer element comprising SEQ ID NO: 1 or a functional derivative thereof. A truncated human cytomegalovirus (CMV) promoter comprising the truncated CMV enhancer element is taught. A polynucleotide expression cassette comprising the truncated CMV promoter and a transcribable polynucleotide operably linked to the truncated CMV promoter polynucleotide construct, a host cell comprising the polynucleotide expression cassette, and use of the host cell treat renal, vascular, pulmonary, or cardiac disease in the patient are taught.

The present application provides, inter alia, methods of treating tenosynovial giant cell tumor in a patient in need thereof, wherein the methods comprise administering to the patient a compound represented by Formula (I). Formula (I).

Provided are methods of digital therapeutics for individuals with benign connective tissue tumor. More specifically, the digital therapeutics are designed to modulate Tenosynovial Giant Cell Tumor (TGCT), on a standalone basis or by combining them with pharmaceutical drugs such as CSF1R inhibitors.

The present disclosure provides compositions and methods for intra-articular delivery of anti-CSF1R antibodies to a joint that is impacted by a disease that is treatable with CSF1 / CSF1R inhibition and / or that expresses CSF1R. It was conventional knowledge that the intra-articular dwell time of proteins in joints is typically a few hours or less. The present disclosure shows, however, that intra-articular delivery of an anti-CSF1R antibody can lead to sustained exposure and pharmacologic activity of the antibody in the joints far beyond a few hours, providing an effective means for targeted and extended delivery of the therapeutic agent.

Disclosed herein are CMV-specific CARs. In some embodiments. the present invention is directed to a method of treating, reducing, or inhibiting an infection by a cytomegalovirus in a subject, which comprises administering to the subject (a) an expression vector that encodes a CMV-specific CAR as described herein, or (b) one or more cells that are transduced with the expression vector.

T cells expressing a chimeric antigen receptor and a T cell receptor specific for CMV (bi-specific T cells) are described as a methods for using such cells in immunotherapy. In the immunotherapy methods, the recipient can be exposed to a CMV vaccine in order to expand and / or stimulate the be-specific T cells.

CD8 + T cells comprising multispecific T-cell receptors and methods for making the same are provided.SOLUTION: A method of generating CD8 + T-cells comprising multispecific T-cell receptors (TCRs), the method comprising: (a) administering to a subject a recombinant cytomegalovirus (CMV) vector comprising a first heterologous antigen-encoding nucleotide sequence; (b) identifying a first CD8 + TCR from a first set of the CD8 + T-cells; (c) administering to the subject a second heterologous antigen-encoding nucleotide sequence; (d) isolating one or more CD8 + T-cells from a second set of the CD8 + T-cells; (e) identifying a second CD8 + TCR from the second set of CD8 + T cells; (f) transfecting a third set of CD8 + T cells with an expression vector; and (g) selecting one or more of the third CD8 + TCRs having the highest avidity for a particular peptide of interest.SELECTED DRAWING: None

The invention provides bidirectional expression vectors comprising Chinese hamster ovary elongation factor 1-α (CHEF1) transcriptional regulatory DNA elements, a gene of interest (GOI), a minimal cytomegalovirus (minCMV) and a selectable marker (SM) and / or a human adenovirus tripartite leader (AdTPL) sequence. The invention also provides method for increasing heterologous protein expression in a host cell comprising culturing the host cell the bidirectional expression vector(s).

To provide a biocompatible membrane composite capable of providing an environment capable of mitigating or controlling a foreign body reaction.SOLUTION: The membrane composite includes a conformable layer and a vascularizing layer. A reinforcing component can optionally be included to provide support to the biocompatible membrane composite invivo and prevent distortion of the membrane composite. The relief layer may be coupled or attached to the implantable device and / or the cell system. The biocompatible membrane composite can be used as a surface layer for implantable devices or cell systems that require vascularization for function but require protection from a host immune response, such as the formation of foreign body giant cells. The biocompatible membrane composite can partially or completely cover the exterior of the implantable device or cell system. The relief layer is positioned between the implantable device or bioactive scaffold and the vascularizing layer.SELECTED DRAWING: Figure 7

The present invention relates to a polypeptide composition, comprising a nucleic acid encoding a mutant pp65 polypeptide, the nucleic acid being mRNA, viral RNA, or replicon RNA. The composition is capable of expressing the mutant pp65 polypeptide in vivo, eliciting a specific humoral or cellular immune response against the pp65 polypeptide, and producing an effector cell having a tumor cell killing effect and a specific antibody.

The present disclosure is directed to methods for treating giant cell arteritis (GCA) using upadacitinib.

Oligomer nucleotides, compositions, methods, kits, and uses are provided for detecting or quantifying a Human Cytomegalovirus virus 1 (CMV (human herpesvirus 5, HHV5) nucleic acid, e.g., using nucleic acid amplification and hybridization assays. Multiphase amplification of a CMV target sequence is also described. The oligomer nucleotides, compositions, methods, kits, and uses can be used to amplify and / or detect the UL56 gene of CMV.

The present disclosure relates to methods for treating giant cell arteritis (GCA), using IL-17 antagonists, e.g., secukinumab. Also disclosed herein are uses of IL-17 antagonists, e.g., IL-17 antibodies, such as secukinumab, for treating GCA patients, as well as medicaments, dosing regimens, pharmaceutical formulations, dosage forms, and kits for use in the disclosed uses and methods.

Described herein are methods of treating cancers and other tumors related to the decreased proliferation, the depletion, or the repolarization of tumor-associated macrophages (TAMs) and treatment of associated disorders, including tenosynovial giant cell tumor (TGCT) and diffuse-type tenosynovial giant cell tumor (DTGCT).

Provided are methods of digital therapeutics for individuals with benign connective tissue tumor. More specifically, the digital therapeutics are designed to modulate Tenosynovial Giant Cell Tumor (TGCT), on a standalone basis or by combining them with pharmaceutical drugs such as CSF1R inhibitors.

The present invention provides binding molecules having one or more of (preferably all of) highly specific binding to the US28 protein of human cytomegalovirus (HCMV), very low levels of non-specific binding to healthy (non-infected) cells, and / or a strain-agnostic binding ability, as well as nucleic acid molecules encoding the said binding molecules. The binding molecules are designed to bind to a newly-identified epitopic region within extracellular domain 1 (ECD1) of a US28 protein of human cytomegalovirus (HCMV), the first of the four extracellular domains presented by US28, corresponding to positions 1 to 37 of the US28 protein sequence as defined by SEQ ID NO:5. The binding molecules of the present invention have been demonstrated to have excellent binding properties, including particular binding specificity for aggressive and / or metastasizing HCMV-infected cancers, including breast cancers. In certain preferred embodiments, the binding molecule is selected from an antibody (including, for example, a BiTE antibody) and a chimeric antigen receptor (CAR), or functional variants, fragments, fusion proteins, and / or conjugates thereof. Also provided are cells expressing said binding molecules, such as CAR-expressing cells, including CAR-T cells, CAR-NK cells, and CAR-M cells.

A method to prevent a disease, comprising: (1) administering a peptide comprising Delta6PV into a subject comprising a human or an animal; wherein the disease comprises one of more of Type 1 diabetes, rheumatoid arthritis, lupus, Sjogren's syndrome, multiple sclerosis, Graves' disease, giant cell arteritis, ankylosing spondylitis, and Guillain Barre Syndrome; and (2) monitoring the disease in the subject.

Disclosed herein are therapeutic compositions that comprise a population of T cells that express chimeric antigens (CAR T cells) specific for a cancer or tumour antigen and are capable or binding to a collection of epitopes derived from cytomegalovirus (CMV), and methods of treating cancer with the use of therapeutic compositions. Also disclosed are antigenic peptides derived from CMV, that are useful in the manufacture of improved CAR T cells. More specifically, disclose herein are uses and methods of treating diseases and conditions, including cancer.

To provide compositions and methods for amplifying, detecting or quantifying a human cytomegalovirus.SOLUTION: Oligomer nucleotides, compositions, methods, kits and uses are provided for detecting or quantifying a Human Cytomegalovirus virus 1 (CMV (human herpesvirus 5, HHV5)) nucleic acid, e.g., using nucleic acid amplification and hybridization assays. Multiphase amplification of a CMV target sequence is also described. The oligomer nucleotides, compositions, methods, kits and uses can be used to amplify and / or detect the UL56 gene of CMV.SELECTED DRAWING: None

The present application relates to a specific probe for detecting HCMV and a kit for isothermal amplification of HCMV, and belongs to the technical field of human cytomegalovirus detection.A specific probe for detecting HCMV, the probe comprises a sequence comprising a T7 promoter SEQ ID NO.21 and a sequence capable of recognizing a Cas13 protein SEQ ID NO.22.The present application uses the genomic RNA of the sample to be tested as a template, uses a specific primer probe set, performs isothermal amplification and CRISPR / Cas13 specific detection, and determines the results according to the fluorescence signal, so as to realize the qualitative detection of the infection state of human cytomegalovirus.Using RNA as a template, the latent state and active state of HCMV can be distinguished.

The present invention relates to a treatment regime, including an antibody or antigen-binding fragment which is capable of binding specifically to colony stimulating factor-1 receptor (CSF-1R) for use in the treatment of tenosynovial giant cell tumour (TGCT) in a subject, as well as associated uses and methods.

The present invention relates to virus-like particles of plant virus Cucumber Mosaic Virus (CMV), and in particular to modified VLPs of CMV comprising Th cell epitopes, in particular universal Th cell epitopes. Furthermore, these modified VLPs serve as, preferably, vaccine platform, for generating immune responses, in particular antibody responses, against antigens linked to said modified VLPs. The presence of the Th cell epitopes, in particular universal Th cell epitopes, led to a further increase in the generated immune response.

The present disclosure relates to processes for preparing (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide, solid state forms thereof, and corresponding pharmaceutical compositions, methods of treatment (including treatment of rheumatoid arthritis and vasculitis), kits, methods of synthesis, and products-by-process. In various aspects, provided are methods for treating giant cell arteritis (GCA).